Infectious Disease Pharmacotherapy

Infectious disease pharmacotherapy is the disease-state area covering the use of antimicrobial agents—antibacterials, antivirals, antifungals, and antiparasitics—to prevent and treat infection. It is distinctive in clinical pharmacy because treatment must consider not only the patient but the pathogen and the wider problem of resistance, making antimicrobial stewardship a defining concern.

Definition

Infectious disease pharmacotherapy is the evidence-based selection, dosing, and monitoring of antimicrobial agents to eradicate or control infection while minimizing toxicity and the emergence of resistance.

Scope

The entry surveys how antimicrobial therapy is selected based on likely or identified pathogens, susceptibility, and pharmacokinetic-pharmacodynamic principles, and how stewardship programs govern appropriate use. It is a reference overview of how anti-infective therapy is organized and stewarded, not a source of individual prescribing or dosing advice.

Core questions

• How is empiric versus targeted antimicrobial therapy chosen?
• What pharmacokinetic-pharmacodynamic principles guide antimicrobial dosing strategies?
• How do antimicrobial stewardship programs balance individual treatment with population-level resistance?

Key concepts

• Empiric and targeted antimicrobial therapy
• Antimicrobial susceptibility and resistance
• Pharmacokinetic-pharmacodynamic dosing (time- vs concentration-dependent killing)
• Antimicrobial stewardship
• Spectrum of activity
• De-escalation and source control

Mechanisms

Antimicrobial agents act selectively on microbial targets—cell-wall synthesis, protein synthesis, nucleic-acid replication, or metabolic pathways—exploiting differences from host cells. Effective therapy depends on matching the drug's spectrum to the pathogen and on pharmacokinetic-pharmacodynamic relationships that distinguish concentration-dependent from time-dependent killing. Resistance arises through selection pressure, which is why stewardship interventions such as de-escalation and duration limits, codified in the IDSA/SHEA stewardship guidelines, are integral to the discipline.

Clinical relevance

Infectious disease pharmacotherapy is a core hospital-pharmacy domain because antimicrobials are among the most frequently prescribed and most frequently misused medications, and pharmacists play a central role in stewardship. This entry describes how anti-infective therapy and stewardship are structured; it is educational and does not provide dosing or individualized treatment recommendations.

Epidemiology

Infectious diseases remain a major global cause of morbidity and mortality, and antimicrobial resistance is recognized as a growing public-health threat that raises the burden of otherwise treatable infections. Healthcare-associated infections, including intravascular catheter-related bloodstream infections addressed by dedicated prevention guidelines, are an important hospital-level target.

Evidence & guidelines

The field is guided by syndrome- and pathogen-specific guidelines from bodies such as the Infectious Diseases Society of America, by antimicrobial stewardship guidelines from IDSA and SHEA, and by infection-prevention guidelines such as those for intravascular catheter-related infections. Reference textbooks like DiPiro's Pharmacotherapy organize this knowledge by infection site and organism.

History

Antimicrobial chemotherapy was transformed by the introduction of sulfonamides and penicillin in the mid-twentieth century, followed by successive classes of antibacterials, antivirals, and antifungals. As resistance emerged, the field shifted from simple agent selection toward formal stewardship, consolidated in the 2010s by IDSA/SHEA implementation guidelines that frame appropriate use as a system-level responsibility.

Debates

How long should antimicrobial courses be?

Traditional fixed durations are increasingly challenged by evidence supporting shorter courses for many infections, with stewardship programs weighing cure rates against resistance selection and adverse effects.

Seminal works

• barlam-2016
• ogrady-2011

Frequently asked questions

Why is antimicrobial stewardship part of infectious disease pharmacotherapy?

Because antimicrobial use directly drives resistance, stewardship programs guide appropriate selection, dosing, de-escalation, and duration so that individual treatment does not unnecessarily compromise the effectiveness of these drugs for the wider population.

What is the difference between empiric and targeted therapy?

Empiric therapy is started before the pathogen is identified, based on the most likely organisms and local susceptibility patterns; targeted (or definitive) therapy is the narrower regimen chosen once culture and susceptibility results are available.